Terms: = Germ cell tumor AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306 AND Prognosis
23 results:
1. Genomic alterations of oligodendrogliomas at distant recurrence.
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
[TBL] [Abstract] [Full Text] [Related]
2. lncRNA TRHDE-AS1 Correlated with Genomic Landscape and Clinical Outcome in Glioma.
Xie J; Lin Y; Li Y; Fang A; Li X; Wang S; Li W
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239411
[TBL] [Abstract] [Full Text] [Related]
3. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
[TBL] [Abstract] [Full Text] [Related]
4. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract] [Full Text] [Related]
5. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
[TBL] [Abstract] [Full Text] [Related]
6. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract] [Full Text] [Related]
7. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Benevides Silva FA; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Neurooncol; 2021 Oct; 155(1):13-23. PubMed ID: 34570300
[TBL] [Abstract] [Full Text] [Related]
8. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract] [Full Text] [Related]
9. Oligodendroglial tumours: subventricular zone involvement and seizure history are associated with cic mutation status.
Liu Z; Liu H; Liu Z; Zhang J
BMC Neurol; 2019 Jun; 19(1):134. PubMed ID: 31215432
[TBL] [Abstract] [Full Text] [Related]
10. The germline Variants rs61757955 and rs34988193 Are Predictive of Survival in Lower Grade Glioma Patients.
Chatrath A; Kiran M; Kumar P; Ratan A; Dutta A
Mol Cancer Res; 2019 May; 17(5):1075-1086. PubMed ID: 30651372
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.
Sim J; Nam DH; Kim Y; Lee IH; Choi JW; Sa JK; Suh YL
Med Oncol; 2018 Mar; 35(5):60. PubMed ID: 29600313
[TBL] [Abstract] [Full Text] [Related]
12. [Diagnostic and prognostic roles of loss of cic protein expression in oligodendroglial tumors].
Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
[No Abstract] [Full Text] [Related]
13. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract] [Full Text] [Related]
14. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Tanboon J; Williams EA; Louis DN
J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
[TBL] [Abstract] [Full Text] [Related]
15. TCF12 is mutated in anaplastic oligodendroglioma.
Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
[TBL] [Abstract] [Full Text] [Related]
16. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract] [Full Text] [Related]
17. Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.
Sahebjam S; McNamara MG; Mason WP
CNS Oncol; 2013 Jul; 2(4):351-8. PubMed ID: 25054579
[TBL] [Abstract] [Full Text] [Related]
18. Loss of cic and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
[TBL] [Abstract] [Full Text] [Related]
19. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract] [Full Text] [Related]
20. Frequent ATRX, cic, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
[TBL] [Abstract] [Full Text] [Related]
[Next]
